NOVEL TUMOR ANTIGEN USEFUL IN DIAGNOSIS AND THERAPY OF BLADDER, OVARY, LUNG AND KIDNEY CANCERS

摘要

Compositions for the diagnosis and therapy of bladder, lung, ovary, and kidneycancer, derived from or based on a normally prostate-specific, androgen-regulated, cell membrane associated an secreted serine protease termed20P1F12/TMPRSS2 are described. A full length cDNA comprising the entire codingsequence of the 20P1F12/TMPRSS2 gene (also designated 20P1F12-GTC1 herein) isprovided (Figure 1). Among the compositions provided are antibodies that bindto 20P1F12/MPRSS2 proteins and polypeptide fragments thereof, includingantibodies labeled with a detectable marker or toxin or therapeuticcomposition. The invention also provides prognostic and diagnostic methods ofexamining a biological sample for evidence of disregulated cellular growth bycomparing the status of 20P1F12/TMPRSS2 in a corresponding normal sample,wherein alterations in the status of 20P1F12/TMPRSS2 in the biological sampleare associated with disregulated cellular growth. The invention furtherprovides various therapeutic compositions and strategies for treating bladder,lung, ovary, and kidney cancer, including particularly, 20P1F12/TMPRSS2antibody therapy methods and compositions, cancer vaccines, and small moleculetherapy.